TY - JOUR
T1 - Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission
AU - Hisamatsu, Tadakazu
AU - Ono, Nobukazu
AU - Imaizumi, Akira
AU - Mori, Maiko
AU - Suzuki, Hiroaki
AU - Uo, Michihide
AU - Hashimoto, Masaki
AU - Naganuma, Makoto
AU - Matsuoka, Katsuyoshi
AU - Mizuno, Shinta
AU - Kitazume, Mina T.
AU - Yajima, Tomoharu
AU - Ogata, Haruhiko
AU - Iwao, Yasushi
AU - Hibi, Toshifumi
AU - Kanai, Takanori
N1 - Funding Information:
The authors have read the journal’s policy and have the following conflicts: Nobukazu Ono, Akira Imaizumi, and Maiko Mori are employees of Ajinomoto Co., Inc. Hiroaki Suzuki, Michihide Uo, and Masaki Hashimoto are employees of Ajinomoto Pharmaceuticals Co., Ltd. Tadakazu Hisamatsu, Toshifumi Hibi, and Takanori Kanai received research grants from Ajinomoto Co., Inc., and Ajinomoto Pharmaceuticals Co., Ltd. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Publisher Copyright:
© 2015 Hisamatsu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/10/16
Y1 - 2015/10/16
N2 - Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age-and genderadjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (logrank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.
AB - Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age-and genderadjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (logrank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.
UR - http://www.scopus.com/inward/record.url?scp=84949033008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949033008&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0140716
DO - 10.1371/journal.pone.0140716
M3 - Article
C2 - 26474176
AN - SCOPUS:84949033008
SN - 1932-6203
VL - 10
JO - PLoS One
JF - PLoS One
IS - 10
M1 - e0140716
ER -